Rapid advances in the field of diabetes technology have led to the development of automated insulin delivery systems (AIDs), which combine an insulin pump and a dosing algorithm that dynamically controls the insulin infusion rate based on continuous glucose monitoring. This evidence concerns the gene INS and diabetes mellitus.